Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
40
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| TANG KEVIN | 10% Owner | 2 | $594.7K | $0 | 2026-07-17 |
| TANG CAPITAL MANAGEMENT LLC | 10% Owner | 4 | $891.1K | $0 | 2026-07-15 |
| Banks Sonja | Director | 6 | $0 | $0 | 2026-06-30 |
| Ezekowitz Alan | Director | 11 | $0 | $65.7K | 2026-06-30 |
| Hill Colin | Director | 3 | $0 | $0 | 2026-06-30 |
| Haviland Kate | Director | 8 | $0 | $0 | 2026-06-30 |
| Dorton Katina | Director | 7 | $0 | $0 | 2026-06-30 |
| King Rachel K. | Director | 3 | $0 | $0 | 2026-06-30 |
| Gould Robert J | See Remarks | 54 | $0 | $5.10M | 2026-06-30 |
| GERAGHTY JAMES A | Director | 9 | $91.6K | $0 | 2026-06-30 |
| Lehrer-Graiwer Joshua | Director | 1 | $0 | $0 | 2026-04-23 |
| Tourangeau Greg | Vice President, Finance | 12 | $0 | $62.3K | 2026-02-02 |
| Oltmans Curtis Gale | SVP, General Counsel | 10 | $9.8K | $44.6K | 2026-02-02 |
| Sapir Alex | See Remarks | 5 | $492.1K | $0 | 2026-02-02 |
| Musso Alan A | Chief Financial Officer | 5 | $0 | $0 | 2026-02-02 |
| RA Capital Healthcare Fund LP | 10% Owner | 5 | $1.32M | $58.38M | 2025-12-08 |
| Shah Rajeev M. | 10% Owner | 2 | $0 | $0 | 2024-08-21 |
| Collins James J. | Director | 6 | $0 | $0 | 2024-06-17 |
| Horn Patrick Taylor | Chief Medical Officer | 1 | $0 | $0 | 2024-03-18 |
| Hayes Melvin H. III | Chief Operating Officer | 3 | $0 | $0 | 2023-04-26 |
| Rajavelu Esther | Chief Financial Officer | 2 | $0 | $0 | 2023-02-09 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 4 | $38.08M | $0 | 2023-01-20 |
| Kolchinsky Peter | 10% Owner | 2 | $607.3K | $0 | 2022-12-27 |
| TRV GP III, LLC | 10% Owner | 1 | $0 | $0 | 2022-12-13 |
| Arroyo Santiago | Chief Medical Officer | 1 | $0 | $0 | 2022-11-07 |
| Morabito Christopher | Chief Medical Officer | 3 | $10.1K | $0 | 2022-01-19 |
| Dunn Judith | See Remarks | 2 | $0 | $0 | 2022-01-19 |
| Thomson Peter G. | VP Finance & Accounting | 15 | $20.7K | $456.3K | 2022-01-19 |
| Stuart Bryan | See Remarks | 11 | $0 | $1.23M | 2022-01-19 |
| STARR KEVIN P | 10% Owner | 6 | $1.30M | $0 | 2021-11-10 |
| LEVIN MARK J | Director, 10% Owner | 7 | $1.30M | $0 | 2021-11-10 |
| Moxham Christopher | Chief Scientific Officer | 7 | $0 | $911.4K | 2021-08-10 |
| Wallace Owen B. | Chief Scientific Officer | 22 | $0 | $245.4K | 2020-09-14 |
| Cadavid Diego | See Remarks | 33 | $0 | $205.8K | 2020-07-01 |
| Section 32 Fund 2, LP | 10% Owner | 2 | $0 | $0 | 2019-07-22 |
| 6 Dimensions Capital, L.P. | 10% Owner | 3 | $1.90M | $0 | 2019-07-22 |
| Third Rock Ventures GP IV, L.P. | 10% Owner | 3 | $1.30M | $0 | 2019-07-22 |
| Casdin Partners Master Fund, L.P. | 10% Owner | 5 | $2.22M | $0 | 2019-07-22 |
| GLAXOSMITHKLINE PLC | 10% Owner | 2 | $0 | $0 | 2019-07-22 |
| Sanofi | 10% Owner | 3 | $1.50M | $0 | 2019-07-22 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| TANG KEVIN | 10% Owner | P Buy | 2026-07-17 | 2026-07-20 | 50,945 | $3.52 | $179.3K | 7,080,945 | SEC↗ |
| TANG KEVIN | 10% Owner | P Buy | 2026-07-16 | 2026-07-20 | 116,671 | $3.56 | $415.3K | 7,030,000 | SEC↗ |
| TANG CAPITAL MANAGEMENT LLC | 10% Owner | P Buy | 2026-07-15 | 2026-07-15 | 107,377 | $3.56 | $382.3K | 6,913,329 | SEC↗ |
| TANG CAPITAL MANAGEMENT LLC | 10% Owner | P Buy | 2026-07-14 | 2026-07-15 | 53,651 | $3.56 | $191.0K | 6,730,000 | SEC↗ |
| TANG CAPITAL MANAGEMENT LLC | 10% Owner | P Buy | 2026-07-14 | 2026-07-15 | 75,952 | $3.58 | $271.9K | 6,805,952 | SEC↗ |
| TANG CAPITAL MANAGEMENT LLC | 10% Owner | P Buy | 2026-07-13 | 2026-07-15 | 12,966 | $3.54 | $45.9K | 6,676,349 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2026-06-30 | 2026-07-02 | 32,000 | — | $0 | 32,000 | SEC↗ |
| Hill Colin | Director | A Award deriv | 2026-06-30 | 2026-07-02 | 32,000 | — | $0 | 32,000 | SEC↗ |
| GERAGHTY JAMES A | Director | A Award deriv | 2026-06-30 | 2026-07-02 | 32,000 | — | $0 | 32,000 | SEC↗ |
| King Rachel K. | Director | A Award deriv | 2026-06-30 | 2026-07-02 | 32,000 | — | $0 | 32,000 | SEC↗ |
| Haviland Kate | Director | A Award deriv | 2026-06-30 | 2026-07-02 | 32,000 | — | $0 | 32,000 | SEC↗ |
| Gould Robert J | Director | A Award deriv | 2026-06-30 | 2026-07-02 | 32,000 | — | $0 | 32,000 | SEC↗ |
| Dorton Katina | Director | A Award deriv | 2026-06-30 | 2026-07-02 | 32,000 | — | $0 | 32,000 | SEC↗ |
| Banks Sonja | Director | A Award deriv | 2026-06-30 | 2026-07-02 | 32,000 | — | $0 | 32,000 | SEC↗ |
| Ezekowitz Alan | Director | S Sale | 2026-06-26 | 2026-06-30 | 18,000 | $3.65 | $65.7K | 10,927 | SEC↗ |
| Lehrer-Graiwer Joshua | Director | A Award deriv | 2026-04-23 | 2026-05-01 | 64,000 | — | $0 | 64,000 | SEC↗ |
| Sapir Alex | See Remarks | A Award deriv | 2026-02-02 | 2026-02-04 | 650,000 | — | $0 | 650,000 | SEC↗ |
| Musso Alan A | Chief Financial Officer | A Award deriv | 2026-02-02 | 2026-02-04 | 170,000 | — | $0 | 170,000 | SEC↗ |
| Tourangeau Greg | Principal Accounting Officer | A Award deriv | 2026-02-02 | 2026-02-04 | 57,000 | — | $0 | 57,000 | SEC↗ |
| Oltmans Curtis Gale | Chief Legal Officer | A Award deriv | 2026-02-02 | 2026-02-04 | 170,000 | — | $0 | 170,000 | SEC↗ |
| Gould Robert J | Director | S Sale | 2026-02-02 | 2026-02-04 | 15,000 | $10.72 | $160.8K | 454,864 | SEC↗ |
| Gould Robert J | Director | S Sale | 2026-01-02 | 2026-01-06 | 15,000 | $11.87 | $178.1K | 469,864 | SEC↗ |
| Gould Robert J | Director | S Sale | 2026-01-02 | 2026-02-04 | 15,000 | $10.87 | $163.1K | 469,864 | SEC↗ |
| Oltmans Curtis Gale | Chief Legal Officer | S Sale | 2025-12-15 | 2025-12-17 | 3,452 | $12.92 | $44.6K | 10,252 | SEC↗ |
| RA Capital Healthcare Fund LP | 10% Owner | S Sale | 2025-12-08 | 2025-12-10 | 2,706,397 | $14.28 | $38.65M | 6,145,682 | SEC↗ |
| RA Capital Healthcare Fund LP | 10% Owner | S Sale | 2025-12-08 | 2025-12-10 | 91,722 | $14.98 | $1.37M | 6,053,960 | SEC↗ |
| RA Capital Healthcare Fund LP | 10% Owner | S Sale | 2025-12-08 | 2025-12-10 | 1,377,020 | $13.33 | $18.36M | 8,852,079 | SEC↗ |
| Gould Robert J | Director | S Sale | 2025-11-19 | 2025-11-21 | 15,000 | $11.03 | $165.4K | 484,864 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2025-06-26 | 2025-06-30 | 36,000 | — | $0 | 36,000 | SEC↗ |
| Gould Robert J | Director | A Award deriv | 2025-06-26 | 2025-06-30 | 36,000 | — | $0 | 36,000 | SEC↗ |
| Banks Sonja | Director | A Award deriv | 2025-06-26 | 2025-06-30 | 36,000 | — | $0 | 36,000 | SEC↗ |
| Hill Colin | Director | A Award deriv | 2025-06-26 | 2025-06-30 | 36,000 | — | $0 | 36,000 | SEC↗ |
| Haviland Kate | Director | A Award deriv | 2025-06-26 | 2025-06-30 | 36,000 | — | $0 | 36,000 | SEC↗ |
| Dorton Katina | Director | A Award deriv | 2025-06-26 | 2025-06-30 | 36,000 | — | $0 | 36,000 | SEC↗ |
| GERAGHTY JAMES A | Director | A Award deriv | 2025-06-26 | 2025-06-30 | 36,000 | — | $0 | 36,000 | SEC↗ |
| King Rachel K. | Director | A Award deriv | 2025-06-26 | 2025-06-30 | 36,000 | — | $0 | 36,000 | SEC↗ |
| Tourangeau Greg | Principal Accounting Officer | S Sale | 2025-05-08 | 2025-05-09 | 498 | $5.06 | $2.5K | 14,062 | SEC↗ |
| Oltmans Curtis Gale | Chief Legal Officer | A Award deriv | 2025-01-24 | 2025-01-28 | 225,000 | — | $0 | 225,000 | SEC↗ |
| Tourangeau Greg | Principal Accounting Officer | A Award deriv | 2025-01-24 | 2025-01-28 | 76,120 | — | $0 | 76,120 | SEC↗ |
| Sapir Alex | See Remarks | A Award deriv | 2025-01-24 | 2025-01-28 | 582,000 | — | $0 | 582,000 | SEC↗ |
| Musso Alan A | Chief Financial Officer | A Award deriv | 2025-01-24 | 2025-01-28 | 285,000 | — | $0 | 285,000 | SEC↗ |
| King Rachel K. | Director | A Award deriv | 2024-11-12 | 2024-11-14 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Shah Rajeev M. | 10% Owner | J Other deriv | 2024-08-21 | 2024-08-23 | 8,500,000 | — | $0 | 8,500,000 | SEC↗ |
| Shah Rajeev M. | 10% Owner | J Other | 2024-08-21 | 2024-08-23 | 8,500,000 | — | $0 | 3,109,704 | SEC↗ |
| Sapir Alex | See Remarks | M Exercise deriv | 2024-07-03 | 2024-07-08 | 150,000 | — | $0 | 2,280,400 | SEC↗ |
| Sapir Alex | See Remarks | M Exercise | 2024-07-03 | 2024-07-08 | 150,000 | $3.27 | $490.5K | 193,360 | SEC↗ |
| Hill Colin | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Banks Sonja | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Collins James J. | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| GERAGHTY JAMES A | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Dorton Katina | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Haviland Kate | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Gould Robert J | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Tourangeau Greg | Principal Accounting Officer | S Sale | 2024-05-07 | 2024-05-09 | 236 | $7.76 | $1.8K | 11,571 | SEC↗ |
| Horn Patrick Taylor | Chief Medical Officer | A Award deriv | 2024-03-18 | 2024-03-20 | 400,000 | — | $0 | 400,000 | SEC↗ |
| Tourangeau Greg | Vice President, Finance | S Sale | 2024-03-08 | 2024-03-08 | 4,884 | $11.72 | $57.2K | 11,807 | SEC↗ |
| Sapir Alex | See Remarks | P Buy | 2024-03-04 | 2024-03-05 | 43,360 | $11.35 | $492.1K | 43,360 | SEC↗ |
| Oltmans Curtis Gale | Chief Legal Officer | A Award deriv | 2024-01-26 | 2024-01-30 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Musso Alan A | Chief Financial Officer | A Award deriv | 2024-01-26 | 2024-01-30 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Tourangeau Greg | Vice President, Finance | A Award deriv | 2024-01-26 | 2024-01-30 | 83,820 | — | $0 | 83,820 | SEC↗ |
| Tourangeau Greg | Vice President, Finance | A Award deriv | 2024-01-26 | 2024-01-30 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Musso Alan A | Chief Financial Officer | A Award deriv | 2024-01-17 | 2024-01-19 | 61,822 | — | $0 | 61,822 | SEC↗ |
| Musso Alan A | Chief Financial Officer | A Award deriv | 2023-08-07 | 2023-08-09 | 432,800 | — | $0 | 432,800 | SEC↗ |
| Collins James J. | Director | A Award deriv | 2023-06-27 | 2023-06-29 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Gould Robert J | Interim President & CEO | A Award deriv | 2023-06-27 | 2023-06-29 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2023-06-27 | 2023-06-29 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Dorton Katina | Director | A Award deriv | 2023-06-27 | 2023-06-29 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Haviland Kate | Director | A Award deriv | 2023-06-27 | 2023-06-29 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Banks Sonja | Director | A Award deriv | 2023-06-27 | 2023-06-29 | 30,000 | — | $0 | 30,000 | SEC↗ |
| GERAGHTY JAMES A | Director | A Award deriv | 2023-06-27 | 2023-06-29 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Tourangeau Greg | Principal Accounting Officer | S Sale | 2023-05-10 | 2023-05-11 | 210 | $3.31 | $695 | 15,992 | SEC↗ |
| Oltmans Curtis Gale | Chief Legal Officer | A Award deriv | 2023-04-26 | 2023-04-28 | 127,500 | — | $0 | 127,500 | SEC↗ |
| Hayes Melvin H. III | Chief Operating Officer | A Award deriv | 2023-04-26 | 2023-04-28 | 115,000 | — | $0 | 115,000 | SEC↗ |
| Rajavelu Esther | Chief Financial Officer | A Award deriv | 2023-02-09 | 2023-02-13 | 160,000 | — | $0 | 160,000 | SEC↗ |
| Hayes Melvin H. III | Chief Operating Officer | A Award deriv | 2023-02-09 | 2023-02-13 | 135,000 | — | $0 | 135,000 | SEC↗ |
| Tourangeau Greg | Controller | A Award deriv | 2023-02-09 | 2023-02-13 | 16,100 | — | $0 | 16,100 | SEC↗ |
| Oltmans Curtis Gale | Chief Legal Officer | A Award deriv | 2023-02-09 | 2023-02-13 | 150,000 | — | $0 | 150,000 | SEC↗ |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P Buy | 2023-01-20 | 2023-01-24 | 1,923,076 | $13.00 | $25.00M | 11,609,704 | SEC↗ |
| Gould Robert J | Interim President & CEO | S Sale | 2023-01-13 | 2023-01-13 | 6,766 | $15.00 | $101.5K | 499,864 | SEC↗ |
| RA Capital Healthcare Fund LP | 10% Owner | P Buy | 2023-01-04 | 2023-01-06 | 122,334 | $7.03 | $860.0K | 9,628,259 | SEC↗ |
| RA Capital Healthcare Fund LP | 10% Owner | P Buy | 2023-01-04 | 2023-01-06 | 58,369 | $7.80 | $455.3K | 9,686,628 | SEC↗ |
| Kolchinsky Peter | 10% Owner | P Buy | 2022-12-27 | 2022-12-29 | 4,089 | $5.99 | $24.5K | 9,505,925 | SEC↗ |
| Kolchinsky Peter | 10% Owner | P Buy | 2022-12-19 | 2022-12-21 | 98,787 | $5.90 | $582.8K | 9,501,836 | SEC↗ |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P Buy | 2022-12-16 | 2022-12-16 | 1,341,420 | $5.42 | $7.27M | 9,403,049 | SEC↗ |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P Buy | 2022-12-15 | 2022-12-16 | 237,029 | $5.50 | $1.30M | 8,061,629 | SEC↗ |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P Buy | 2022-12-14 | 2022-12-16 | 824,600 | $5.46 | $4.50M | 7,824,600 | SEC↗ |
| TRV GP III, LLC | 10% Owner | J Other | 2022-12-13 | 2022-12-15 | 2,000,000 | — | $0 | 1,962,202 | SEC↗ |
| Arroyo Santiago | Chief Medical Officer | A Award deriv | 2022-11-07 | 2022-11-09 | 400,000 | — | $0 | 400,000 | SEC↗ |
| Oltmans Curtis Gale | Chief Legal Officer | A Award deriv | 2022-08-09 | 2022-08-11 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Hayes Melvin H. III | Chief Operating Officer | A Award deriv | 2022-08-09 | 2022-08-11 | 137,000 | — | $0 | 137,000 | SEC↗ |
| Tourangeau Greg | Controller | A Award deriv | 2022-07-15 | 2022-07-19 | 16,540 | — | $0 | 16,540 | SEC↗ |
| Ezekowitz Alan | Director | J Other deriv | 2022-06-28 | 2022-06-29 | 500 | — | $0 | 14,500 | SEC↗ |
| Collins James J. | Director | A Award deriv | 2022-06-27 | 2022-06-29 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Banks Sonja | Director | A Award deriv | 2022-06-27 | 2022-06-29 | 19,000 | — | $0 | 19,000 | SEC↗ |
| GERAGHTY JAMES A | Director | A Award deriv | 2022-06-27 | 2022-06-29 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Haviland Kate | Director | A Award deriv | 2022-06-27 | 2022-06-29 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Dorton Katina | Director | A Award deriv | 2022-06-27 | 2022-06-29 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Gould Robert J | Director | A Award deriv | 2022-06-27 | 2022-06-29 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2022-06-27 | 2022-06-29 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Gould Robert J | Director | M Exercise deriv | 2022-06-07 | 2022-06-08 | 71,435 | — | $0 | 86,523 | SEC↗ |
| Gould Robert J | Director | M Exercise | 2022-06-07 | 2022-06-08 | 71,435 | $7.84 | $560.1K | 578,065 | SEC↗ |
| Gould Robert J | Director | S Sale | 2022-06-07 | 2022-06-08 | 71,435 | $8.09 | $577.9K | 506,630 | SEC↗ |
| Gould Robert J | Director | M Exercise deriv | 2022-06-06 | 2022-06-06 | 24,382 | — | $0 | 157,958 | SEC↗ |
| Gould Robert J | Director | M Exercise | 2022-06-06 | 2022-06-06 | 24,382 | $7.84 | $191.2K | 531,012 | SEC↗ |
| Gould Robert J | Director | S Sale | 2022-06-06 | 2022-06-06 | 24,382 | $8.10 | $197.5K | 506,630 | SEC↗ |
| Gould Robert J | Director | M Exercise deriv | 2022-06-03 | 2022-06-06 | 25,551 | — | $0 | 182,340 | SEC↗ |
| Gould Robert J | Director | M Exercise | 2022-06-03 | 2022-06-06 | 25,551 | $7.84 | $200.3K | 532,181 | SEC↗ |
| Gould Robert J | Director | S Sale | 2022-06-03 | 2022-06-06 | 25,551 | $7.95 | $203.1K | 506,630 | SEC↗ |
| Gould Robert J | Director | M Exercise deriv | 2022-06-02 | 2022-06-06 | 16,689 | — | $0 | 207,891 | SEC↗ |
| Gould Robert J | Director | M Exercise | 2022-06-02 | 2022-06-06 | 16,689 | $7.84 | $130.8K | 523,319 | SEC↗ |
| Gould Robert J | Director | S Sale | 2022-06-02 | 2022-06-06 | 16,689 | $7.92 | $132.2K | 506,630 | SEC↗ |
| Tourangeau Greg | Controller | A Award deriv | 2022-05-06 | 2022-05-10 | 6,500 | — | $0 | 6,500 | SEC↗ |
| Tourangeau Greg | Controller | A Award | 2022-05-06 | 2022-05-10 | 3,250 | — | $0 | 16,202 | SEC↗ |
| Gould Robert J | Director | M Exercise deriv | 2022-04-07 | 2022-04-11 | 5,631 | — | $0 | 224,580 | SEC↗ |
| Gould Robert J | Director | M Exercise | 2022-04-07 | 2022-04-11 | 5,631 | $7.84 | $44.1K | 512,261 | SEC↗ |
| Gould Robert J | Director | S Sale | 2022-04-07 | 2022-04-11 | 5,631 | $24.02 | $135.3K | 506,630 | SEC↗ |
| Gould Robert J | Director | M Exercise deriv | 2022-04-05 | 2022-04-05 | 52,552 | — | $0 | 230,211 | SEC↗ |
| Gould Robert J | Director | M Exercise | 2022-04-05 | 2022-04-05 | 52,552 | $7.84 | $412.0K | 559,182 | SEC↗ |
| Gould Robert J | Director | S Sale | 2022-04-05 | 2022-04-05 | 52,552 | $24.26 | $1.27M | 506,630 | SEC↗ |
| Gould Robert J | Director | M Exercise deriv | 2022-04-04 | 2022-04-05 | 7,235 | — | $0 | 282,763 | SEC↗ |
| Gould Robert J | Director | M Exercise | 2022-04-04 | 2022-04-05 | 7,235 | $7.84 | $56.7K | 513,865 | SEC↗ |
| Gould Robert J | Director | S Sale | 2022-04-04 | 2022-04-05 | 7,235 | $24.02 | $173.8K | 506,630 | SEC↗ |
| Gould Robert J | Director | M Exercise deriv | 2022-04-01 | 2022-04-05 | 34,464 | — | $0 | 289,998 | SEC↗ |
| Gould Robert J | Director | S Sale | 2022-04-01 | 2022-04-05 | 34,464 | $24.03 | $828.2K | 506,630 | SEC↗ |
| Gould Robert J | Director | M Exercise | 2022-04-01 | 2022-04-05 | 34,464 | $7.84 | $270.2K | 541,094 | SEC↗ |
| Oltmans Curtis Gale | SVP, General Counsel | A Award deriv | 2022-01-19 | 2022-01-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Morabito Christopher | Chief Medical Officer | A Award deriv | 2022-01-19 | 2022-01-21 | 59,744 | — | $0 | 59,744 | SEC↗ |
| Stuart Bryan | See Remarks | A Award deriv | 2022-01-19 | 2022-01-21 | 340,000 | — | $0 | 340,000 | SEC↗ |
| Dunn Judith | See Remarks | A Award deriv | 2022-01-19 | 2022-01-21 | 140,890 | — | $0 | 140,890 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | A Award deriv | 2022-01-19 | 2022-01-21 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Rajavelu Esther | Chief Financial Officer | A Award deriv | 2022-01-03 | 2022-01-10 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Banks Sonja | Director | A Award deriv | 2021-12-08 | 2021-12-09 | 30,000 | — | $0 | 30,000 | SEC↗ |
| STARR KEVIN P | 10% Owner | J Other | 2021-11-10 | 2021-11-12 | 1,000,000 | — | $0 | 3,962,202 | SEC↗ |
| LEVIN MARK J | Director, 10% Owner | J Other | 2021-11-10 | 2021-11-12 | 1,000,000 | — | $0 | 3,962,202 | SEC↗ |
| STARR KEVIN P | 10% Owner | J Other | 2021-09-22 | 2021-09-24 | 1,000,000 | — | $0 | 4,962,202 | SEC↗ |
| LEVIN MARK J | Director, 10% Owner | J Other | 2021-09-22 | 2021-09-24 | 1,000,000 | — | $0 | 4,962,202 | SEC↗ |
| Stuart Bryan | See Remarks | M Exercise deriv | 2021-08-11 | 2021-08-12 | 28,000 | — | $0 | 243,571 | SEC↗ |
| Stuart Bryan | See Remarks | S Sale | 2021-08-11 | 2021-08-12 | 28,000 | $23.75 | $665.0K | 0 | SEC↗ |
| Stuart Bryan | See Remarks | M Exercise | 2021-08-11 | 2021-08-12 | 28,000 | $7.84 | $219.5K | 28,000 | SEC↗ |
| Stuart Bryan | See Remarks | M Exercise deriv | 2021-08-10 | 2021-08-12 | 32,000 | — | $0 | 271,571 | SEC↗ |
| Moxham Christopher | Chief Scientific Officer | M Exercise deriv | 2021-08-10 | 2021-08-12 | 20,714 | — | $0 | 103,572 | SEC↗ |
| Moxham Christopher | Chief Scientific Officer | M Exercise deriv | 2021-08-10 | 2021-08-12 | 31,071 | — | $0 | 72,501 | SEC↗ |
| Stuart Bryan | See Remarks | M Exercise | 2021-08-10 | 2021-08-12 | 32,000 | $7.84 | $250.9K | 32,000 | SEC↗ |
| Stuart Bryan | See Remarks | S Sale | 2021-08-10 | 2021-08-12 | 32,000 | $17.50 | $560.0K | 0 | SEC↗ |
| Moxham Christopher | Chief Scientific Officer | M Exercise | 2021-08-10 | 2021-08-12 | 20,714 | $7.84 | $162.4K | 20,714 | SEC↗ |
| Moxham Christopher | Chief Scientific Officer | S Sale | 2021-08-10 | 2021-08-12 | 20,714 | $17.00 | $352.1K | 0 | SEC↗ |
| Moxham Christopher | Chief Scientific Officer | M Exercise | 2021-08-10 | 2021-08-12 | 31,071 | $7.84 | $243.6K | 31,071 | SEC↗ |
| Moxham Christopher | Chief Scientific Officer | S Sale | 2021-08-10 | 2021-08-12 | 31,071 | $18.00 | $559.3K | 0 | SEC↗ |
| GERAGHTY JAMES A | Director | P Buy | 2021-06-28 | 2021-06-29 | 10,000 | $9.16 | $91.6K | 90,714 | SEC↗ |
| Oltmans Curtis Gale | SVP, General Counsel | P Buy | 2021-06-28 | 2021-06-29 | 1,088 | $9.01 | $9.8K | 1,088 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | P Buy | 2021-06-28 | 2021-06-29 | 2,300 | $9.00 | $20.7K | 2,300 | SEC↗ |
| Morabito Christopher | Chief Medical Officer | P Buy | 2021-06-28 | 2021-06-29 | 1,100 | $9.16 | $10.1K | 1,100 | SEC↗ |
| Dorton Katina | Director | A Award deriv | 2021-06-09 | 2021-06-11 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Haviland Kate | Director | A Award deriv | 2021-06-09 | 2021-06-11 | 15,000 | — | $0 | 15,000 | SEC↗ |
| GERAGHTY JAMES A | Director | A Award deriv | 2021-06-09 | 2021-06-11 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2021-06-09 | 2021-06-11 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Collins James J. | Director | A Award deriv | 2021-06-09 | 2021-06-11 | 15,000 | — | $0 | 15,000 | SEC↗ |
| LEVIN MARK J | Director | A Award deriv | 2021-06-09 | 2021-06-11 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Morabito Christopher | Chief Medical Officer | A Award deriv | 2021-05-10 | 2021-05-12 | 163,000 | — | $0 | 163,000 | SEC↗ |
| Dunn Judith | See Remarks | A Award deriv | 2021-04-01 | 2021-04-02 | 215,000 | — | $0 | 215,000 | SEC↗ |
| Stuart Bryan | See Remarks | A Award deriv | 2021-03-31 | 2021-04-02 | 350,000 | — | $0 | 350,000 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2021-03-16 | 2021-03-17 | 789 | $12.43 | $9.8K | 506,630 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2021-03-15 | 2021-03-17 | 9,211 | $12.13 | $111.7K | 507,419 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | M Exercise deriv | 2021-02-22 | 2021-02-24 | 5,000 | — | $0 | 50,471 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | S Sale | 2021-02-22 | 2021-02-24 | 5,000 | $14.72 | $73.6K | 15,212 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | M Exercise | 2021-02-22 | 2021-02-24 | 5,000 | $7.84 | $39.2K | 20,212 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2021-02-16 | 2021-02-18 | 1,673 | $14.56 | $24.4K | 516,630 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2021-02-16 | 2021-02-18 | 6,542 | $14.19 | $92.8K | 518,303 | SEC↗ |
| Moxham Christopher | Chief Scientific Officer | A Award deriv | 2021-02-08 | 2021-02-10 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Gould Robert J | See Remarks | A Award deriv | 2021-02-02 | 2021-02-04 | 269,390 | — | $0 | 269,390 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | A Award deriv | 2021-01-25 | 2021-01-27 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Stuart Bryan | Chief Operating Officer | A Award deriv | 2021-01-25 | 2021-01-27 | 134,376 | — | $0 | 134,376 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | S Sale | 2021-01-21 | 2021-01-25 | 6,607 | $14.00 | $92.5K | 15,212 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2021-01-20 | 2021-01-22 | 10,000 | $12.08 | $120.8K | 524,845 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2020-12-03 | 2020-12-07 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Oltmans Curtis Gale | SVP, General Counsel | A Award deriv | 2020-12-03 | 2020-12-07 | 153,600 | — | $0 | 153,600 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise deriv | 2020-09-14 | 2020-09-14 | 6,350 | — | $0 | 75,592 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise | 2020-09-14 | 2020-09-14 | 6,350 | $7.84 | $49.8K | 133,438 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise deriv | 2020-07-08 | 2020-07-09 | 2,951 | — | $0 | 81,942 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-07-08 | 2020-07-09 | 2,500 | $20.00 | $50.0K | 534,845 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | S Sale | 2020-07-08 | 2020-07-09 | 2,951 | $20.00 | $59.0K | 127,088 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise | 2020-07-08 | 2020-07-09 | 2,951 | $7.84 | $23.1K | 130,039 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-07-01 | 2020-07-02 | 1,071 | $18.30 | $19.6K | 65,714 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise deriv | 2020-06-30 | 2020-07-01 | 141 | — | $0 | 84,893 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise | 2020-06-30 | 2020-07-01 | 141 | $7.84 | $1.1K | 127,229 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | S Sale | 2020-06-30 | 2020-07-01 | 141 | $20.00 | $2.8K | 127,088 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise deriv | 2020-06-25 | 2020-06-26 | 1,459 | — | $0 | 12,277 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-06-25 | 2020-06-26 | 2,500 | $20.80 | $52.0K | 537,345 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise | 2020-06-25 | 2020-06-26 | 1,459 | $4.83 | $7.0K | 68,244 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-06-25 | 2020-06-26 | 1,459 | $22.00 | $32.1K | 66,785 | SEC↗ |
| Haviland Kate | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 9,285 | — | $0 | 9,285 | SEC↗ |
| Collins James J. | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 9,285 | — | $0 | 9,285 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 9,285 | — | $0 | 9,285 | SEC↗ |
| GERAGHTY JAMES A | Director | A Award deriv | 2020-06-11 | 2020-06-15 | 9,285 | — | $0 | 9,285 | SEC↗ |
| LEVIN MARK J | Director, 10% Owner | A Award deriv | 2020-06-11 | 2020-06-15 | 9,285 | — | $0 | 9,285 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise deriv | 2020-06-10 | 2020-06-12 | 401 | — | $0 | 13,736 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-06-10 | 2020-06-12 | 401 | $22.00 | $8.8K | 66,785 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise | 2020-06-10 | 2020-06-12 | 401 | $4.83 | $1.9K | 67,186 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-06-09 | 2020-06-10 | 156 | $20.00 | $3.1K | 539,845 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise deriv | 2020-06-05 | 2020-06-08 | 451 | — | $0 | 14,137 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise | 2020-06-05 | 2020-06-08 | 451 | $4.83 | $2.2K | 67,236 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-06-05 | 2020-06-08 | 451 | $20.18 | $9.1K | 66,785 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-06-05 | 2020-06-09 | 3,433 | $20.17 | $69.2K | 540,001 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise deriv | 2020-06-04 | 2020-06-08 | 226 | — | $0 | 14,588 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-06-04 | 2020-06-05 | 1,300 | $20.04 | $26.1K | 543,434 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-06-04 | 2020-06-08 | 226 | $20.05 | $4.5K | 66,785 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise | 2020-06-04 | 2020-06-08 | 226 | $4.83 | $1.1K | 67,011 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise deriv | 2020-06-03 | 2020-06-04 | 338 | — | $0 | 14,814 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise | 2020-06-03 | 2020-06-04 | 338 | $4.83 | $1.6K | 67,123 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-06-03 | 2020-06-04 | 338 | $20.18 | $6.8K | 66,785 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-06-03 | 2020-06-05 | 1,500 | $20.13 | $30.2K | 544,734 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise deriv | 2020-06-02 | 2020-06-04 | 45 | — | $0 | 15,152 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-06-02 | 2020-06-03 | 2,797 | $20.00 | $55.9K | 546,234 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise | 2020-06-02 | 2020-06-04 | 45 | $4.83 | $217 | 66,830 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-06-02 | 2020-06-04 | 45 | $20.00 | $900 | 66,785 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-06-01 | 2020-06-03 | 5 | $20.00 | $100 | 549,031 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise deriv | 2020-05-29 | 2020-06-01 | 200 | — | $0 | 15,197 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-05-29 | 2020-06-01 | 1,390 | $20.08 | $27.9K | 549,036 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-05-29 | 2020-06-01 | 200 | $20.04 | $4.0K | 66,785 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise | 2020-05-29 | 2020-06-01 | 200 | $4.83 | $966 | 66,985 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise deriv | 2020-05-28 | 2020-06-01 | 2,232 | — | $0 | 85,034 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise deriv | 2020-05-28 | 2020-06-01 | 600 | — | $0 | 15,397 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | S Sale | 2020-05-28 | 2020-06-01 | 2,232 | $20.00 | $44.6K | 127,088 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise | 2020-05-28 | 2020-06-01 | 2,232 | $7.84 | $17.5K | 129,320 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-05-28 | 2020-06-01 | 1,919 | $20.01 | $38.4K | 550,426 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise | 2020-05-28 | 2020-06-01 | 600 | $4.83 | $2.9K | 67,385 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-05-28 | 2020-06-01 | 600 | $20.00 | $12.0K | 66,785 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise deriv | 2020-05-27 | 2020-05-29 | 448 | — | $0 | 87,266 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise | 2020-05-27 | 2020-05-29 | 448 | $7.84 | $3.5K | 127,536 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | S Sale | 2020-05-27 | 2020-05-29 | 448 | $20.00 | $9.0K | 127,088 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise deriv | 2020-05-26 | 2020-05-28 | 412 | — | $0 | 87,714 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-05-26 | 2020-05-28 | 2,500 | $20.00 | $50.0K | 552,345 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise | 2020-05-26 | 2020-05-28 | 412 | $7.84 | $3.2K | 127,500 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | S Sale | 2020-05-26 | 2020-05-28 | 412 | $20.00 | $8.2K | 127,088 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise deriv | 2020-05-12 | 2020-05-12 | 1,860 | — | $0 | 15,997 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-05-12 | 2020-05-12 | 1,860 | $18.00 | $33.5K | 66,785 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | M Exercise | 2020-05-12 | 2020-05-12 | 1,860 | $4.83 | $9.0K | 68,645 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | S Sale | 2020-05-11 | 2020-05-12 | 7,500 | $16.00 | $120.0K | 21,071 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-03-02 | 2020-03-02 | 315 | $18.13 | $5.7K | 66,785 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-03-02 | 2020-03-02 | 1,828 | $17.26 | $31.6K | 67,100 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | S Sale | 2020-02-24 | 2020-02-26 | 2,102 | $17.43 | $36.6K | 28,821 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | S Sale | 2020-02-24 | 2020-02-26 | 2,648 | $16.18 | $42.8K | 30,923 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | S Sale | 2020-02-24 | 2020-02-26 | 250 | $18.61 | $4.7K | 28,571 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise deriv | 2020-02-19 | 2020-02-20 | 6,088 | — | $0 | 88,126 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | S Sale | 2020-02-19 | 2020-02-20 | 6,088 | $20.00 | $121.8K | 127,088 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | M Exercise | 2020-02-19 | 2020-02-20 | 6,088 | $7.84 | $47.7K | 133,176 | SEC↗ |
| Gould Robert J | See Remarks | S Sale | 2020-02-19 | 2020-02-20 | 2,500 | $20.00 | $50.0K | 554,845 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | S Sale | 2020-02-03 | 2020-02-05 | 2,143 | $17.33 | $37.1K | 68,928 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | A Award deriv | 2020-01-23 | 2020-01-27 | 58,900 | — | $0 | 58,900 | SEC↗ |
| Gould Robert J | President & CEO | A Award deriv | 2020-01-23 | 2020-01-27 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | A Award deriv | 2020-01-23 | 2020-01-27 | 33,100 | — | $0 | 33,100 | SEC↗ |
| Cadavid Diego | SVP Clinical Development | A Award deriv | 2020-01-23 | 2020-01-27 | 55,440 | — | $0 | 55,440 | SEC↗ |
| Stuart Bryan | Chief Operating Officer | A Award deriv | 2020-01-23 | 2020-01-27 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | S Sale | 2020-01-23 | 2020-01-27 | 4,738 | $17.17 | $81.4K | 33,833 | SEC↗ |
| Thomson Peter G. | VP Finance & Accounting | S Sale | 2020-01-23 | 2020-01-27 | 262 | $18.05 | $4.7K | 33,571 | SEC↗ |
| Dorton Katina | Director | A Award deriv | 2020-01-02 | 2020-01-06 | 18,571 | — | $0 | 18,571 | SEC↗ |
| Section 32 Fund 2, LP | 10% Owner | C Conversion deriv | 2019-07-22 | 2019-07-22 | 3,250,000 | — | $0 | 0 | SEC↗ |
| LEVIN MARK J | Director, 10% Owner | C Conversion deriv | 2019-07-22 | 2019-07-22 | 39,166,667 | — | $0 | 0 | SEC↗ |
| Casdin Partners Master Fund, L | 10% Owner | C Conversion deriv | 2019-07-22 | 2019-07-22 | 3,250,000 | — | $0 | 0 | SEC↗ |
| 6 Dimensions Capital, L.P. | 10% Owner | C Conversion deriv | 2019-07-22 | 2019-07-22 | 3,087,500 | — | $0 | 0 | SEC↗ |
| STARR KEVIN P | 10% Owner | C Conversion deriv | 2019-07-22 | 2019-07-22 | 39,166,667 | — | $0 | 0 | SEC↗ |
| STARR KEVIN P | 10% Owner | C Conversion deriv | 2019-07-22 | 2019-07-22 | 0 | — | $0 | 0 | SEC↗ |
| Third Rock Ventures GP IV, L.P | 10% Owner | C Conversion deriv | 2019-07-22 | 2019-07-22 | 15,833,333 | — | $0 | 0 | SEC↗ |
| Sanofi | 10% Owner | C Conversion deriv | 2019-07-22 | 2019-07-23 | 3,250,000 | — | $0 | 0 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion deriv | 2019-07-22 | 2019-07-24 | 12,500,000 | — | $0 | 0 | SEC↗ |
| Section 32 Fund 2, LP | 10% Owner | C Conversion | 2019-07-22 | 2019-07-22 | 464,285 | — | $0 | 464,285 | SEC↗ |
| LEVIN MARK J | Director, 10% Owner | P Buy | 2019-07-22 | 2019-07-22 | 81,250 | $16.00 | $1.30M | 5,962,202 | SEC↗ |
| LEVIN MARK J | Director, 10% Owner | C Conversion | 2019-07-22 | 2019-07-22 | 5,595,238 | — | $0 | 5,880,952 | SEC↗ |
| Casdin Partners Master Fund, L | 10% Owner | C Conversion | 2019-07-22 | 2019-07-22 | 464,285 | — | $0 | 464,285 | SEC↗ |
| Casdin Partners Master Fund, L | 10% Owner | P Buy | 2019-07-22 | 2019-07-22 | 5,000 | $14.50 | $72.5K | 604,285 | SEC↗ |
| Casdin Partners Master Fund, L | 10% Owner | P Buy | 2019-07-22 | 2019-07-22 | 125,000 | $16.00 | $2.00M | 589,285 | SEC↗ |
| Casdin Partners Master Fund, L | 10% Owner | P Buy | 2019-07-22 | 2019-07-22 | 10,000 | $14.50 | $145.0K | 599,285 | SEC↗ |
| 6 Dimensions Capital, L.P. | 10% Owner | P Buy | 2019-07-22 | 2019-07-22 | 118,750 | $16.00 | $1.90M | 559,821 | SEC↗ |
| 6 Dimensions Capital, L.P. | 10% Owner | C Conversion | 2019-07-22 | 2019-07-22 | 441,071 | — | $0 | 441,071 | SEC↗ |
| STARR KEVIN P | 10% Owner | C Conversion | 2019-07-22 | 2019-07-22 | 5,595,238 | — | $0 | 5,880,952 | SEC↗ |
| STARR KEVIN P | 10% Owner | P Buy | 2019-07-22 | 2019-07-22 | 81,250 | $16.00 | $1.30M | 5,962,202 | SEC↗ |
| Third Rock Ventures GP IV, L.P | 10% Owner | C Conversion | 2019-07-22 | 2019-07-22 | 2,261,904 | — | $0 | 2,261,904 | SEC↗ |
| Third Rock Ventures GP IV, L.P | 10% Owner | P Buy | 2019-07-22 | 2019-07-22 | 81,250 | $16.00 | $1.30M | 2,343,154 | SEC↗ |
| Sanofi | 10% Owner | P Buy | 2019-07-22 | 2019-07-23 | 93,750 | $16.00 | $1.50M | 558,035 | SEC↗ |
| Sanofi | 10% Owner | C Conversion | 2019-07-22 | 2019-07-23 | 464,285 | — | $0 | 464,285 | SEC↗ |
| GLAXOSMITHKLINE PLC | 10% Owner | C Conversion | 2019-07-22 | 2019-07-24 | 1,785,714 | — | $0 | 1,785,714 | SEC↗ |
| Thomson Peter G. | See Remarks | A Award deriv | 2019-07-18 | 2019-07-18 | 7,078 | — | $0 | 7,078 | SEC↗ |
| Stuart Bryan | Chief Operating Officer | A Award deriv | 2019-07-18 | 2019-07-18 | 28,571 | — | $0 | 28,571 | SEC↗ |
| Cadavid Diego | See Remarks | A Award deriv | 2019-07-18 | 2019-07-18 | 12,784 | — | $0 | 12,784 | SEC↗ |
| Gould Robert J | See Remarks | A Award deriv | 2019-07-18 | 2019-07-18 | 107,142 | — | $0 | 107,142 | SEC↗ |
| Haviland Kate | Director | A Award deriv | 2019-07-18 | 2019-07-18 | 9,285 | — | $0 | 9,285 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2019-07-18 | 2019-07-18 | 5,714 | — | $0 | 5,714 | SEC↗ |
| GERAGHTY JAMES A | Director | A Award deriv | 2019-07-18 | 2019-07-18 | 9,285 | — | $0 | 9,285 | SEC↗ |
| Collins James J. | Director | A Award deriv | 2019-07-18 | 2019-07-18 | 5,714 | — | $0 | 5,714 | SEC↗ |
| Wallace Owen B. | Chief Scientific Officer | A Award deriv | 2019-07-18 | 2019-07-18 | 44,493 | — | $0 | 44,493 | SEC↗ |